Background: Invasive ductal carcinoma (IDC) with lobular features (IDC-L) is not recognized as a subtype of breast cancer. We previously showed that IDC-L may be a variant of IDC with clinicopathological characteristics more similar to invasive lobular carcinoma (ILC). We sought to determine the re-excision rates of IDC-L compared with ILC and IDC, and the feasibility of diagnosing IDC-L on core biopsies.
Methods: Surgical procedure, multiple tumor foci, tumor size, and residual invasive carcinoma on re-excision were recorded for IDC-L (n = 178), IDC (n = 636), and ILC (n = 251). Re-excision rates were calculated by excluding mastectomy as first procedure cases and including only re-excisions for invasive carcinoma. Slides of correlating core biopsies for IDC-L cases initially diagnosed as IDC were re-reviewed.
Results: For T2 tumors (2.1-5.0 cm), re-excision rates for IDC-L (76 %) and ILC (88 %) were higher than that for IDC (42 %) (p = 0.003). Multiple tumor foci were more common in IDC-L (31 %) and ILC (26 %) than IDC (7 %) (p < 0.0001), which was a significant factor in higher re-excision rates when compared with a single tumor focus (p < 0.001). Ninety-two of 149 patients (62 %) with IDC-L were diagnosed on core biopsies. Of the 44 patients initially diagnosed as IDC, 30 were re-reviewed, of which 24 (80 %) were re-classified as IDC-L.
Conclusions: Similar to ILC, re-excision rates for IDC-L are higher than IDC for larger tumors. Patients may need to be counseled about the higher likelihood of additional procedures to achieve negative margins. This underscores the importance of distinguishing IDC-L from IDC on core biopsies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-014-3871-7 | DOI Listing |
Cureus
October 2024
Surgical Oncology, Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, PRT.
Background Breast-conserving surgery (BCS) is standard for early breast cancer, yet achieving clear surgical margins remains challenging. Ultrasound (US)-guided BCS has emerged as a potential alternative to wire-guided surgery, but its efficacy compared to traditional methods requires evaluation. Methods A retrospective review of patients undergoing BCS from April 2022 to April 2023 at the Portuguese Institute of Oncology of Porto (IPO-Porto) was conducted.
View Article and Find Full Text PDFJ Craniomaxillofac Surg
November 2024
Department of Oral and Maxillofacial Surgery, German Armed Forces Central Hospital, Rübenacherstr. 170, 56072, Koblenz, Germany.
This study aimed to identify factors influencing the completeness of primary and re-excision of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), and cutaneous carcinoma in situ (CIS) of the head and neck. A retrospective single-center analysis was conducted, encompassing 1513 instances of cutaneous tumors recorded between 2015 and 2022. This dataset comprised 1108 primary excisions and 405 re-excisions, all of which were histologically verified cases of BCC, SCC, and CIS located within the head and neck region.
View Article and Find Full Text PDFCan J Surg
November 2024
From the Division of General Surgery, Department of Surgery, University of Alberta, Edmonton, Alta. (Ryan, Rajaee, Olson, Lesniak, Peiris); the Alberta Health Services Cross Cancer Institute, Department of Medical Oncology, University of Alberta, Edmonton, Alta. (Ghosh); the Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, Alta. (Ghosh)
Background: Re-operation after breast-conserving surgery for invasive breast cancer is variable among centres and individual surgeons. In this study, we aimed to characterize the current landscape of practice regarding re-operation for invasive breast cancer in the province of Alberta.
Methods: This study was a retrospective review of the Synoptec database for patients undergoing primary breast-conserving surgery for invasive breast cancer or reoperation in the province of Alberta in the year 2020.
Breast Cancer Res Treat
November 2024
Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Purpose: With DCIS incidence on the rise, up to 30% of patients undergo mastectomy for Ductal carcinoma in situ (DCIS) (Nash and Hwang, in: Ann Surg Oncol 30(6):3206-3214, 2023). Local recurrence rates after mastectomy for DCIS are reportedly low, but risk factors for recurrence are not known (Kim et al., in: J Cancer Res Ther 16(6):1197-1202, 2020).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!